Global Tourette Syndrome Market By Type (Motor Tics and Vocal Tics), Product Type (Antipsychotics and Non-antipsychotics), Diagnosis (Blood Diagnosis, Imaging Diagnosis, and Others), Drug type (Fluphenazine, Haloperidol, Risperidone, Pimozide, Tetrabenazine, Botulinum (Botox) Injections, Methylphenidate, Dextroamphetamine, Clonidine, Guanfacine, and Fluoxetine), Therapy Type (Behavior Therapy, Psychotherapy, Deep Brain Stimulation (DBS), Comprehensive Behavioral Intervention for Tics (CBIT), and Others), End-User (Hospitals, Clinics, and Others) - Industry Trends and Forecast to 2030.
Tourette Syndrome Market Analysis and Size:
The growing awareness about tourette syndrome is one of the major factors driving the growth of tourette syndrome market. The increase in neurotransmitter disorders and healthcare infrastructure expenditure accelerate the tourette syndrome market growth.
Data Bridge Market Research analyses that the global tourette syndrome market, which was USD 2,501 million in 2022, would rocket up to USD 6,521 million by 2030 and is expected to undergo a CAGR of 4.20 % during the forecast period. Motor tics segment dominates the type segment of the tourette syndrome market owing to the advancements in technology that have led to the development of advancements in diagnosis of tourette syndrome for various use. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Tourette Syndrome Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Global Tourette Syndrome Market By Type (Motor Tics and Vocal Tics), Product Type (Antipsychotics and Non-antipsychotics), Diagnosis (Blood Diagnosis, Imaging Diagnosis, and Others), Drug type (Fluphenazine, Haloperidol, Risperidone, Pimozide, Tetrabenazine, Botulinum (Botox) Injections, Methylphenidate, Dextroamphetamine, Clonidine, Guanfacine, and Fluoxetine), Therapy Type (Behavior Therapy, Psychotherapy, Deep Brain Stimulation (DBS), Comprehensive Behavioral Intervention for Tics (CBIT), and Others), End-User (Hospitals, Clinics, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd.(U.S.), Sun Pharmaceutical Industries Ltd.(India), Pfizer Inc. (U.S.), Otsuka Holdings Co. Ltd.(Japan), Mylan N.V. (U.S.), Johnson & Johnson Services Inc. (U.S.), H. Lundbeck A/S(U.S.), Eli Lilly and Company. (U.S.), Boehringer Ingelheim International GmbH (U.S.), AstraZeneca (U.S.), Catalyst Pharma (U.S.), Neurocrine Biosciences, Inc. (U.S.), Reviva Pharmaceuticals Inc. (U.S.), Therapix Biosciences Ltd. (U.S.), Emalex Biosciences Inc. (U.S.), Beijing PINS Medical Co., Ltd. (Japan), FGK Clinical Research GmbH (Germany), Medtronic (U.S.), and Bausch Health Companies Inc. (U.S.) among others
|
|
Market Opportunities
|
|
Market Definition
The market encompasses various pharmaceutical drugs, therapeutic interventions, diagnostic tests, and supportive care options to alleviate symptoms and improve the quality of life for individuals with Tourette syndrome. It refers to the market for products and services related to diagnosing, treating, and managing Tourette syndrome, a neurological disorder characterized by repetitive, involuntary movements and vocalizations called tics.
Global Tourette Syndrome Market Dynamics
Drivers
- Increasing Awareness and Diagnosis:
Growing awareness about Tourette Syndrome among healthcare professionals and the general population has increased diagnosis rates. As more individuals are diagnosed with Tourette Syndrome, the demand for effective treatments and management options is expected to rise, driving market growth.
- Advancements in Medical Research:
Ongoing advancements in medical research have improved the understanding of Tourette Syndrome's underlying causes and mechanisms. This has facilitated the development of novel therapies and treatment approaches. The progress in research is expected to continue driving the market's growth by providing better treatment options.
- Collaboration and Partnerships:
Collaborative efforts between pharmaceutical companies, research institutions, and advocacy organizations have significantly developed new treatment options for Tourette Syndrome. These partnerships help accelerate the drug discovery process and facilitate the translation of scientific findings into clinical applications.
Opportunities
- Government Initiatives and Support:
Governments and regulatory bodies worldwide increasingly recognize the need to address neurological disorders such as tourette syndrome. They are implementing supportive policies, funding research, and promoting awareness campaigns. These initiatives contribute to the growth of the Tourette Syndrome market by encouraging investment in research and development.
- Increasing Demand for Therapeutic Interventions:
Tourette Syndrome is a chronic condition that significantly impacts the quality of life of affected individuals. There is a growing demand for effective therapeutic interventions to alleviate symptoms and improve daily functioning. This demand drives the development and commercialization of new treatment options, including medications, behavioral therapies, and medical devices.
Challenges/ Restraints
- Limited understanding of the underlying cause:
The exact cause of Tourette Syndrome is still not fully understood. This lack of knowledge about the underlying mechanisms of the disorder makes it challenging to develop targeted treatments. The complexity of the condition hampers the progress in finding a definitive cure or highly effective therapies.
- Diagnostic challenges:
Tourette Syndrome can be challenging to diagnose accurately, as its symptoms may overlap with other neurological and psychiatric disorders. The absence of specific diagnostic tests often delays diagnosis and treatment initiation. Improved diagnostic tools and criteria are needed to ensure early identification of patients with Tourette Syndrome.
This global tourette syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global tourette syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In May 2023, Teva Pharmaceutical Industries Ltd. announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the company’s strong commercial portfolio with AUSTEDO, AJOVY, UZEDYTM, and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse, and focus the business
- In November 2022, A wholly-owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and associate companies) and Sun Pharma Advanced Research Company Ltd.
Global Tourette Syndrome Market scope
The global tourette syndrome market is segmented on the basis of type, product type, diagnosis, drug type, therapy type, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
By Type
- Motor Tics
- Vocal Tics
By Product Type
- Antipsychotics
- Non-antipsychotics
By diagnosis
- Blood Diagnosis
- Imaging Diagnosis
- Others
By drug type
- Fluphenazine
- Haloperidol
- Risperidone
- Pimozide
- Tetrabenazine
- Botulinum (Botox) Injections
- Methylphenidate
- Dextroamphetamine
- Clonidine
- Guanfacine
- Fluoxetine
By Therapy Type
- Behavior Therapy
- Psychotherapy
- Deep Brain Stimulation (DBS)
- Comprehensive Behavioral Intervention for Tics (CBIT)
- Others
By End-User
- Hospitals
- Clinics
- Others
Global Tourette Syndrome Market regional analysis/insights
The global tourette syndrome market is analysed and market size insights and trends are provided basis type, product type, diagnosis, drug type, therapy type, and end user as referenced above.
The countries covered in the Global Tourette Syndrome Market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa.
North America dominates the tourette syndrome market due to major key players, high disposable income, high healthcare expenditure, and a well-developed healthcare sector in this region.
Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities, rising investment in the healthcare sector, and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The global tourette syndrome market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Global Tourette Syndrome Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Global Tourette Syndrome Market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Tourette Syndrome Market Share Analysis
The global tourette syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Global Tourette Syndrome Market.
Some of the major players operating in the global tourette syndrome market are:
- Teva Pharmaceutical Industries Ltd.(U.S.)
- Sun Pharmaceutical Industries Ltd.(India)
- Pfizer Inc. (U.S.)
- Otsuka Holdings Co. Ltd.(Japan)
- Mylan N.V. (U.S.)
- Johnson & Johnson Services Inc. (U.S.)
- H. Lundbeck A/S(U.S.)
- Eli Lilly and Company. (U.S.)
- Boehringer Ingelheim International GmbH (U.S.)
- AstraZeneca (U.S.)
- Catalyst Pharma (U.S.)
- Neurocrine Biosciences, Inc. (U.S.)
- Reviva Pharmaceuticals Inc. (U.S.)
- Therapix Biosciences Ltd. (U.S.)
- Emalex Biosciences Inc. (U.S.)
- Beijing PINS Medical Co., Ltd. (Japan)
- FGK Clinical Research GmbH (Germany)
- Medtronic (U.S.)
- Bausch Health Companies Inc. (U.S.)
SKU-